Gibson, Dunn & Crutcher LLP Advised Biosynth Carbosynth in its Acquisition of Pepscan Therapeutics and Pepscan Presto

July 5, 2022

---

Gibson, Dunn & Crutcher LLP advised Biosynth Carbosynth, a portfolio company of the KKR Health Care Growth fund, in its acquisition of Pepscan Therapeutics and Pepscan Presto. More details can be found in the announcement release.

The Gibson Dunn team was led by partner Wim De Vlieger and included partner Till LeFranc and associate Romain Tourenne. Partners Deirdre Taylor, Ali Nikpay and Of Counsel Jessica Staples advised on the antitrust aspects. Of Counsel Richard Roeder and associates Katharina Humphrey, Mariam Pathan and Linda Vogele advised on the compliance aspects.